Dr Greg van Wyk, CEO, Noxopharm Ltd 00:00:00
Noxopharm Limited (ASX:NOX) CEO & CMO Dr Greg van Wyk talks about interim data at 24 weeks for the company's DARRT-1 clinical trial for prostate cancer.
Noxopharm Limited (ASX:NOX) CEO & CMO Dr Greg van Wyk talks about interim data at 24 weeks for the company's DARRT-1 clinical trial for prostate cancer.